These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 9053487

  • 1. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
    Elit LM, Gafni A, Levine MN.
    J Clin Oncol; 1997 Feb; 15(2):632-9. PubMed ID: 9053487
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A, Trippoli S, Becagli P, Tendi E.
    Cancer; 1996 Dec 01; 78(11):2366-73. PubMed ID: 8941008
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacoeconomic profile of taxanes in advanced ovarian cancer.
    Messori A, Trippoli S.
    Anticancer Drugs; 1998 Nov 01; 9(10):909-16. PubMed ID: 9890702
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma?
    Covens A, Boucher S, Roche K, Macdonald M, Pettitt D, Jolain B, Souetre E, Rivière M.
    Cancer; 1996 May 15; 77(10):2086-91. PubMed ID: 8640674
    [Abstract] [Full Text] [Related]

  • 11. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
    Dranitsaris G, Elia-Pacitti J, Cottrell W.
    Pharmacoeconomics; 2004 May 15; 22(6):375-87. PubMed ID: 15099123
    [Abstract] [Full Text] [Related]

  • 12. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A, Cecchi M, Becagli P, Trippoli S.
    Cancer; 1997 Jun 01; 79(11):2264-6. PubMed ID: 9179077
    [No Abstract] [Full Text] [Related]

  • 13. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
    Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M.
    Value Health; 2016 Jun 01; 19(4):431-9. PubMed ID: 27325335
    [Abstract] [Full Text] [Related]

  • 14. [A new, more expensive agent against ovarian cancer. Worth its price?].
    Högberg T, Karlsson G, Ridderheim M, Boman K, Frankendal B, Horvath G, Sorbe B, Strang P, Rosenberg P.
    Lakartidningen; 1997 Jan 08; 94(1-2):21-4. PubMed ID: 9053597
    [No Abstract] [Full Text] [Related]

  • 15. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL, Meisner BC, Armstrong DK, Frick KD.
    Gynecol Oncol; 2007 Sep 08; 106(3):476-81. PubMed ID: 17688927
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
    Earle CC, Evans WK.
    Br J Cancer; 1999 May 08; 80(5-6):815-20. PubMed ID: 10360660
    [Abstract] [Full Text] [Related]

  • 17. Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.
    Havrilesky LJ, Garfield CF, Barnett JC, Cohn DE.
    Gynecol Oncol; 2012 Jun 08; 125(3):631-4. PubMed ID: 22446408
    [Abstract] [Full Text] [Related]

  • 18. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
    Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M.
    Pharmacoeconomics; 2002 Jun 08; 20(7):485-97. PubMed ID: 12093304
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer.
    Limwattananon S, Limwattananon C, Maoleekulpairoj S, Soparatanapaisal N.
    J Med Assoc Thai; 2006 May 08; 89(5):690-8. PubMed ID: 16756057
    [Abstract] [Full Text] [Related]

  • 20. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM.
    J Clin Oncol; 2011 Apr 01; 29(10):1247-51. PubMed ID: 21383297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.